Form 4: Regulus Therapeutics Director Acquires Stock Options
SEC Form 4 Filing
Director Alice Shih-hou Huang acquired 60,000 stock options in Regulus Therapeutics on May 20, 2024.
Summary
- Alice Shih-hou Huang, a director of Regulus Therapeutics Inc., acquired 60,000 stock options on May 20, 2024.
- The exercise price of these options is $2.01.
- The options vest ratably over twelve months, becoming fully vested one year after the grant date or at the next annual shareholder meeting, contingent upon continuous service.
- The options expire on May 19, 2034.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing regarding stock option grants, which is neutral in sentiment.
Industry Context
This is a standard Form 4 filing, reflecting a transaction by a company insider. Option grants are a common form of executive compensation in the biotech industry.
Stakeholder Impact
- The transaction could have a minor positive impact on shareholder sentiment, as it signals confidence from a company director.
Key Dates
| Date | Description |
|---|---|
| 05/20/2024 | Date of transaction: acquisition of stock options. |
| 05/19/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.